Who Paid My Doc
Vivek Subbiah
Pediatric Hematology-Oncology Houston, TX Medical Doctor
NPI 1174726384 CMS profile 189527
1515 Holcombe Blvd, # 87, Houston, TX 77030
General payments
$194,074
Research payments
$10,573
Ownership & investment interest
$0
Research they led as principal investigator
$21,154,371
Through program year 2025, Vivek Subbiah of Houston, TX is reported in the CMS Open Payments database as having received $194,074 across 173 general payments and $10,573 in research payments paid to them. Separately, studies naming them as principal investigator received $21,154,371 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $48,973 | 74 | |
| 2025 | Research | $1,489 | 1 | |
| 2024 | General | $19,081 | 35 | |
| 2023 | General | $24,690 | 20 | |
| 2023 | Research | $3,431 | 3 | |
| 2022 | General | $43,304 | 11 | |
| 2022 | Research | $1,930 | 4 | |
| 2021 | General | $19,903 | 10 | |
| 2021 | Research | $2,540 | 4 | |
| 2020 | General | $18,822 | 5 | |
| 2020 | Research | $1,184 | 1 | |
| 2019 | General | $19,301 | 18 |
Beside peers
- Vivek Subbiah
- Pediatric Hematology-Oncology median
- Middle half of Pediatric Hematology-Oncology
- National median
In program year 2025, general payments to Vivek Subbiah were reported at $48,973. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.
Show as a table
| Year | Vivek Subbiah | Pediatric Hematology-Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $19,301 | $184 | $69–$2,094 | $163 |
| 2020 | $18,822 | $220 | $37–$3,941 | $114 |
| 2021 | $19,903 | $366 | $63–$4,909 | $132 |
| 2022 | $43,304 | $181 | $66–$2,775 | $149 |
| 2023 | $24,690 | $175 | $62–$2,600 | $160 |
| 2024 | $19,081 | $227 | $66–$2,992 | $164 |
| 2025 | $48,973 | $204 | $80–$2,819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 70 billing codesPaid by Medicare
$321,977
Medicare patients
67
Services billed
9,527
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Cancer | 60% | |
| Arthritis | 34% | |
| Depression | 25% | |
| Ischemic heart disease | 24% | |
| Diabetes | 18% | |
| Chronic kidney disease | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Infusion, normal saline solution , 1000 cc J7030 | Office | 18 | 25 | $52 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 13 | 187 | $16 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 18 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| RETEVMO |
|
$3,250 | — | — |
| TAFINLAR |
|
$2,438 | — | — |
| MEKINIST |
|
$2,438 | — | — |
| LORBRENA |
|
$2,025 | — | — |
| TAGRISSO |
|
$1,422 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 18 in the dashboard with a free accountRecords
186 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Hematology-Oncology in Texas
Stanton Goldman
Pediatric Hematology-Oncology · Dallas, TX
Maurizio Ghisoli
Pediatric Hematology-Oncology · Dallas, TX
Anish Ray
Pediatric Hematology-Oncology · Fort Worth, TX
Joel Weinthal
Pediatric Hematology-Oncology · Dallas, TX
Prasad Mathew
Pediatric Hematology-Oncology · El Paso, TX
Vinod Gidvani-Diaz
Pediatric Hematology-Oncology · San Antonio, TX
Related records
Pediatric Hematology-Oncology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Hematology-Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.